Precision BioSciences Q4 revenue beats analyst estimates on Novartis deal

Precision Biosciences

12/03/2026 11:11

Overview

U.S. gene editing firm's Q4 revenue surged and beat analyst expectations

Company posted Q4 net profit, reversing prior-year loss

Quarterly revenue jump driven by Novartis and Imugene milestone payments

Outlook

Precision expects PBGENE-HBV clinical biomarker and biopsy data in first half of 2026

Company anticipates initial PBGENE-DMD clinical data from multiple patients by year-end 2026

Precision expects cash runway to fund operations through 2028

Result Drivers

COLLABORATION REVENUE - Q4 revenue increase mainly due to $26.2 mln recognized under Novartis agreement and $8 mln from Imugene license

LOWER R&D EXPENSES - Decrease in research and development costs driven by reduced preclinical spending as PBGENE-HBV entered the clinic and shift to PBGENE-DMD

REDUCED ADMINISTRATIVE COSTS - General and administrative expenses fell due to operational discipline and lower employee-related costs

Company press release: ID:nBw72bcHLa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$34.20 mln
$9.08 mln (4 Analysts)
Q4 Net Income
$20.13 mln
Q4 Income from Operations
$12.51 mln
Q4 Operating Expenses
$21.70 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Precision BioSciences Inc is $25.50, about 404% above its March 11 closing price of $5.06

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)